Sandoz ends US generic Advair deal with Vectura
This article was originally published in Scrip
Executive Summary
Sandoz, Novartis's generics arm, is handing back the US rights for Vectura 's VR315, a combination product for asthma/chronic obstructive pulmonary disease (COPD), which is widely believed to be a generic version of GlaxoSmithKline's best-selling long-acting beta-agonist (LABA) Seretide/Advair (salmeterol and fluticasone) for the US market.